MAPT and Parkinson disease: It is intriguing that treatment with 7,8-DHF can reduce pathological hyperphosphorylated tau and α-synuclein compared to the rotenone group (p-α-synuclein/α-synuclein: 24.52 ± 4.56% vs 36.21 ± 4.24%, p < 0.05; p-tau: 16.43 ± 2.62% vs 31.20 ± 5.95%, p < 0.01) (Figures 3(f) and 3(g)), suggesting that 7,8-DHF could ameliorate the α-synucleinopathy and tauopathy in the rotenone-induced animal model of PD.